Drug intelligence / Profile preview

XP-104

Development stage: Unknown
Lead developer: Xynomic Pharmaceuticals Holdings
Modality: Small Molecules
Administration: Subcutaneous

Overview

**XP-104** is a small molecule RET kinase inhibitor developed by Xynomic Pharma (also referred to as Xynomic Research Institute and Xynomic Pharmaceuticals) as part of their preclinical oncology pipeline. It targets the RET proto-oncogene, which is implicated in various cancers driven by RET fusions or mutations, particularly those resistant to other therapies. Acquired by Xynomic through global exclusive rights, XP-104 is being investigated for multiple tumors, with no reported clinical trials or development status beyond preclinical stages as of available data.[1][3][5][13]

Targets

RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on XP-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XP-104.

Explore the full profile